Alyeska Investment Group’s aTyr Pharma ATYR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,412,749
| Closed | -$7.16M | – | 743 |
|
|
2025
Q2 | $7.16M | Buy |
1,412,749
+134,852
| +11% | +$531K | 0.03% | 390 |
|
|
2025
Q1 | $3.86M | Sell |
1,277,897
-544
| -0% | -$1.98K | 0.02% | 379 |
|
|
2024
Q4 | $4.63M | Sell |
1,278,441
-450,097
| -26% | -$1.36M | 0.02% | 404 |
|
|
2024
Q3 | $3.04M | Sell |
1,728,538
-139,095
| -7% | -$253K | 0.02% | 389 |
|
|
2024
Q2 | $2.91M | Buy |
1,867,633
+362,078
| +24% | +$630K | 0.02% | 382 |
|
|
2024
Q1 | $2.94M | Sell |
1,505,555
-950,000
| -39% | -$1.66M | 0.02% | 358 |
|
|
2023
Q4 | $3.46M | Hold |
2,455,555
| – | – | 0.02% | 334 |
|
|
2023
Q3 | $3.88M | Buy |
2,455,555
+250,000
| +11% | +$463K | 0.03% | 356 |
|
|
2023
Q2 | $4.76M | Sell |
2,205,555
-267,599
| -11% | -$584K | 0.04% | 336 |
|
|
2023
Q1 | $5.19M | Buy |
2,473,154
+1,094,407
| +79% | +$2.4M | 0.05% | 298 |
|
|
2022
Q4 | $3.02M | Buy |
1,378,747
+300,000
| +28% | +$707K | 0.03% | 292 |
|
|
2022
Q3 | $3.24M | Buy |
1,078,747
+106,421
| +11% | +$357K | 0.04% | 293 |
|
|
2022
Q2 | $2.75M | Buy |
972,326
+211,528
| +28% | +$765K | 0.03% | 370 |
|
|
2022
Q1 | $4.07M | Buy |
760,798
+85,823
| +13% | +$486K | 0.04% | 318 |
|
|
2021
Q4 | $5.04M | Sell |
674,975
-413,689
| -38% | -$3.45M | 0.06% | 277 |
|
|
2021
Q3 | $9.88M | Sell |
1,088,664
-186,083
| -15% | -$1.11M | 0.12% | 200 |
|
|
2021
Q2 | $6.22M | Buy |
1,274,747
+291,153
| +30% | +$1.24M | 0.07% | 297 |
|
|
2021
Q1 | $4.38M | Buy |
983,594
+141,040
| +17% | +$663K | 0.06% | 352 |
|
|
2020
Q4 | $3.27M | Buy |
842,554
+89,908
| +12% | +$329K | 0.05% | 327 |
|
|
2020
Q3 | $2.43M | Buy |
752,646
+26,662
| +4% | +$109K | 0.04% | 331 |
|
|
2020
Q2 | $3.22M | Sell |
725,984
-12,304
| -2% | -$44.7K | 0.05% | 312 |
|
|
2020
Q1 | $2.07M | Buy |
+738,288
| New | +$3.19M | 0.04% | 254 |
|
|
2018
Q3 | – | Sell |
-40,892
| Closed | -$521K | – | 525 |
|
|
2018
Q2 | $521K | Sell |
40,892
-8,982
| -18% | -$213K | ﹤0.01% | 422 |
|
|
2018
Q1 | $1.85M | Sell |
49,874
-449
| -0.9% | -$21K | 0.02% | 351 |
|
|
2017
Q4 | $2.47M | Sell |
50,323
-3,572
| -7% | -$220K | 0.02% | 318 |
|
|
2017
Q3 | $3.81M | Sell |
53,895
-6,052
| -10% | -$280K | 0.03% | 312 |
|
|
2017
Q2 | $2.85M | Buy |
59,947
+2,115
| +4% | +$99K | 0.02% | 319 |
|
|
2017
Q1 | $2.83M | Sell |
57,832
-18,747
| -24% | -$857K | 0.02% | 368 |
|
|
2016
Q4 | $2.31M | Buy |
76,579
+2,284
| +3% | +$93.7K | 0.02% | 383 |
|
|
2016
Q3 | $3.31M | Buy |
74,295
+6,405
| +9% | +$277K | 0.03% | 357 |
|
|
2016
Q2 | $2.64M | Buy |
67,890
+32,836
| +94% | +$1.53M | 0.02% | 351 |
|
|
2016
Q1 | $1.93M | Buy |
35,054
+12,978
| +59% | +$987K | 0.02% | 333 |
|
|
2015
Q4 | $3.04M | Buy |
22,076
+8,920
| +68% | +$1.27M | 0.03% | 279 |
|
|
2015
Q3 | $1.89M | Buy |
13,156
+7,790
| +145% | +$1.78M | 0.02% | 332 |
|
|
2015
Q2 | $1.39M | Buy |
+5,366
| New | +$1.67M | 0.02% | 380 |
|
Other funds holding ATYR
RA
Alyeska Investment Group's ATYR Position: Q3 2025 in Review
Alyeska Investment Group sold out of aTyr Pharma (ATYR) in Q3 2025, closing a stake of 1,412,749 shares — an estimated $7.16M sold.
Alyeska Investment Group first reported a position in ATYR in Q2 2015 and held it in 35 quarters. The position peaked at $9.88M in Q3 2021. 103 funds tracked by Wall St. Rank hold ATYR as of Q3 2025.
- Alyeska Investment Group reported no remaining aTyr Pharma position as of Q3 2025 after selling out during the quarter.
- Alyeska Investment Group sold 1,412,749 aTyr Pharma shares in Q3 2025, an estimated $7.16M.
- Alyeska Investment Group first reported a position in aTyr Pharma in Q2 2015 and held it in 35 quarters.
- Alyeska Investment Group's aTyr Pharma position peaked at $9.88M in Q3 2021.
- 103 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2025.
Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.